These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34192899)

  • 1. Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.
    Shimada YJ; Raita Y; Liang LW; Maurer MS; Hasegawa K; Fifer MA; Reilly MP
    Circ Heart Fail; 2021 Jul; 14(7):e007849. PubMed ID: 34192899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways.
    Liang LW; Hasegawa K; Maurer MS; Reilly MP; Fifer MA; Shimada YJ
    Circ Heart Fail; 2023 Jun; 16(6):e010010. PubMed ID: 37305994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Major Adverse Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy Using Proteomics Profiling.
    Shimada YJ; Raita Y; Liang LW; Maurer MS; Hasegawa K; Fifer MA; Reilly MP
    Circ Genom Precis Med; 2022 Dec; 15(6):e003546. PubMed ID: 36252118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy.
    Shimada YJ; Hasegawa K; Kochav SM; Mohajer P; Jung J; Maurer MS; Reilly MP; Fifer MA
    J Cardiovasc Transl Res; 2019 Dec; 12(6):569-579. PubMed ID: 31278493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.
    Lumish HS; Sherrid MV; Janssen PML; Ferrari G; Hasegawa K; Castillero E; Adlestein E; Swistel DG; Topkara VK; Maurer MS; Reilly MP; Shimada YJ
    J Am Coll Cardiol; 2024 Nov; 84(20):1999-2011. PubMed ID: 39365226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning.
    Captur G; Heywood WE; Coats C; Rosmini S; Patel V; Lopes LR; Collis R; Patel N; Syrris P; Bassett P; O'Brien B; Moon JC; Elliott PM; Mills K
    Mol Cell Proteomics; 2020 Jan; 19(1):114-127. PubMed ID: 31243064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics.
    Lumish HS; Liang LW; Hasegawa K; Maurer MS; Fifer MA; Reilly MP; Shimada YJ
    Heart; 2023 Nov; 109(24):1837-1843. PubMed ID: 37451849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling Pathways Associated With Prior Cardiovascular Events in Hypertrophic Cardiomyopathy.
    Lee C; Liang LW; Hasegawa K; Maurer MS; Tower-Rader A; Fifer MA; Reilly M; Shimada YJ
    J Card Fail; 2024 Mar; 30(3):462-472. PubMed ID: 37562580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
    Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
    Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy.
    Garmany R; Bos JM; Tester DJ; Giudicessi JR; Dos Remedios CG; Dasari S; Nagaraj NK; Nair AA; Johnson KL; Ryan ZC; Maleszewski JJ; Ommen SR; Dearani JA; Ackerman MJ
    Circ Genom Precis Med; 2023 Apr; 16(2):e003756. PubMed ID: 36802768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.
    Hiremath P; Lawler PR; Ho JE; Correia AW; Abbasi SA; Kwong RY; Jerosch-Herold M; Ho CY; Cheng S
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy.
    Liang LW; Raita Y; Hasegawa K; Fifer MA; Maurer MS; Reilly MP; Shimada YJ
    Heart; 2022 Oct; 108(22):1807-1814. PubMed ID: 35351822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.
    Lander BS; Zhao Y; Hasegawa K; Maurer MS; Tower-Rader A; Fifer MA; Reilly MP; Shimada YJ
    Front Cardiovasc Med; 2022; 9():839409. PubMed ID: 35783832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
    Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
    J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy.
    Coats CJ; Heywood WE; Virasami A; Ashrafi N; Syrris P; Dos Remedios C; Treibel TA; Moon JC; Lopes LR; McGregor CGA; Ashworth M; Sebire NJ; McKenna WJ; Mills K; Elliott PM
    Circ Genom Precis Med; 2018 Dec; 11(12):e001974. PubMed ID: 30562113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.
    Hanatani S; Izumiya Y; Takashio S; Kojima S; Yamamuro M; Araki S; Rokutanda T; Tsujita K; Yamamoto E; Tanaka T; Tayama S; Kaikita K; Hokimoto S; Sugiyama S; Ogawa H
    Heart Vessels; 2014 Mar; 29(2):231-7. PubMed ID: 23525862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy.
    Captur G; Doykov I; Chung SC; Field E; Barnes A; Zhang E; Heenan I; Norrish G; Moon JC; Elliott PM; Heywood WE; Mills K; Kaski JP
    Circ Genom Precis Med; 2024 Jun; 17(3):e004448. PubMed ID: 38847081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure.
    Arbustini E; Fasani R; Morbini P; Diegoli M; Grasso M; Dal Bello B; Marangoni E; Banfi P; Banchieri N; Bellini O; Comi G; Narula J; Campana C; Gavazzi A; Danesino C; Viganò M
    Heart; 1998 Dec; 80(6):548-58. PubMed ID: 10065021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
    Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
    Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.